Review of Multimodality Management of Anaplastic Thyroid Cancer

This study has been completed.

Sponsored by:	Alberta Cancer Board
Information provided by:	Alberta Cancer Board
ClinicalTrials.gov Identifier:	NCT00280852

Purpose

To describe the outcome of patients with anaplastic thyroid cancer treated with hyperfractionated radiotherapy and concomitant chemotherapy

Condition
Anaplastic Thyroid Cancer

MedlinePlus related topics: Cancer Thyroid Cancer

Drug Information available for: Thyroid

Study Type:	Observational
Study Design:	Retrospective
Official Title:	A Retrospective Review of Multimodality Management of Anaplastic Thyroid Cancer

Further study details as provided by Alberta Cancer Board:

Estimated Enrollment:	5
Study Start Date:	January 2006
Study Completion Date:	June 2006
Estimated Primary Completion Date:	June 2006 (Final data collection date for primary outcome measure)

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00280852

Locations

Sponsors and Collaborators

Alberta Cancer Board

Investigators

Principal Investigator:

Harold Lau, MD

Alberta Cancerboard

More Information

Study ID Numbers:	18940
Study First Received:	January 20, 2006
Last Updated:	August 15, 2008
ClinicalTrials.gov Identifier:	NCT00280852
Health Authority:	Canada: Health Canada

Keywords provided by Alberta Cancer Board:

anaplastic thyroid cancer
chemotherapy
radiotherapy

Study placed in the following topic categories:

Thyroid Neoplasms
Head and Neck Neoplasms
Endocrine System Diseases
Endocrinopathy

Thyroid cancer, anaplastic
Thyroid Diseases
Endocrine Gland Neoplasms

Additional relevant MeSH terms:

Neoplasms
Neoplasms by Site

ClinicalTrials.gov processed this record on January 15, 2009